Aktis Oncology priced its initial public offering, raising $318 million in what market watchers called the first meaningful biotech IPO of 2026. The upsized offering was led in part by a $100 million purchase from Eli Lilly, signaling industry support for radiopharmaceutical platforms. Aktis is advancing miniprotein radioconjugates including Ac‑AKY‑1189 (Nectin‑4) and AKY‑2519 (B7‑H3). The company says proceeds will fund ongoing phase 1b studies and expand its pipeline; preliminary results from AKY‑1189’s dose‑escalation portion are expected in Q1 2027. The strong pricing and investor demand provide an early test of public-market appetite for novel oncology modalities this year.